Critically, these formulations achieved TMA reduction comparable to that of the synthetic inhibitor (FMC) without compromising gut microbiota diversity or eliminating TMA-producing taxasupporting a targeted, mechanism-based action
Current research done on the potential beneficial effects of metformin has extended to treating diabetic nephropathy (Han et al., 2021), metabolic syndrome (Ladeiras-Lopes et al., 2015), and polycystic ovary syndrome (Peng et al., 2023)
Mol Psychiatry (2021) 26:430014
This medication was first approved by the FDA in December 1998
Important Considerations Individual Variation: Response to these strategies varies based on genetics, current gut health, metabolic status, and lifestyle factors